BlueCross BlueShield of South Carolina (BCBS-SC) issued a positive commercial payor policy covering Paradigm Spine’s coflex® Interlaminar Stabilization® device to treat lumbar spinal stenosis. The policy, titled “Interspinous and Interlaminar Stabilization/Distraction Devices (Spacers),” is dated August 2018.
BCBS-SC is the largest commercial payor in South Carolina, significantly expanding coflex’s patient access.
Other coflex announcements in 2018 include:
In May, NASS issued a policy recommendation for Lumbar Interlaminar Device without Fusion and with Decompression, providing private payors with evidence to allow access for the coflex technology.
Also in May, the coflex Interlaminar Stabilization disposable instrument kit became the first approved disposable spinal instrument set for a Class III spinal device to receive a supplemental FDA PMA.
Paradigm Spine announced positive two-year coflex study results in January.
BlueCross BlueShield of South Carolina (BCBS-SC) issued a positive commercial payor policy covering Paradigm Spine’s coflex® Interlaminar Stabilization® device to treat lumbar spinal stenosis. The policy, titled “Interspinous and Interlaminar Stabilization/Distraction Devices (Spacers),” is dated August 2018.
BCBS-SC is the largest...
BlueCross BlueShield of South Carolina (BCBS-SC) issued a positive commercial payor policy covering Paradigm Spine’s coflex® Interlaminar Stabilization® device to treat lumbar spinal stenosis. The policy, titled “Interspinous and Interlaminar Stabilization/Distraction Devices (Spacers),” is dated August 2018.
BCBS-SC is the largest commercial payor in South Carolina, significantly expanding coflex’s patient access.
Other coflex announcements in 2018 include:
In May, NASS issued a policy recommendation for Lumbar Interlaminar Device without Fusion and with Decompression, providing private payors with evidence to allow access for the coflex technology.
Also in May, the coflex Interlaminar Stabilization disposable instrument kit became the first approved disposable spinal instrument set for a Class III spinal device to receive a supplemental FDA PMA.
Paradigm Spine announced positive two-year coflex study results in January.
Copy to clipboard 
